Plenamine™ 15% is indicated as an amino acid (nitrogen) source in parenteral nutrition regimens. This use is appropriate when the enteral route is inadvisable, inadequate or not possible, as when: — Gastrointestinal absorption is impaired by obstruction, inflammatory disease or its complications, or antineoplastic therapy; — Bowel rest is needed because of gastrointestinal surgery or its complications such as ...
The appropriate daily dose of amino acids to be used with dextrose or with dextrose and intravenous fat emulsion will depend upon the metabolic status and clinical response of the patient as therapy proceeds. Doses which achieve nitrogen equilibrium or positive balance are the most desirable. The dosage on the first day should be approximately half the anticipated optimal dosage and should be increased gradually t...
Package Insert
PHARMACY BULK PACKAGE
NOT FOR DIRECT INFUSION
Protect from light until use.
Plenamine™ 15% Amino Acids Injection in a Pharmacy Bulk Package is a sterile, clear, nonpyrogenic solution of essential and nonessential amino acids for intravenous infusion in parenteral nutrition following appropriate dilution.
Plenamine™ 15% in a Pharmacy Bulk Package is not for direct infusion. It is a sterile dosage form which contains several single doses for use in a pharmacy admixture program in the preparation of intravenous parenteral fluids.
Each 100 mL contains:
| Essential Amino Acids | ||
| Lysine (from Lysine Acetate, USP) | 1.18 | g |
| Leucine, USP | 1.04 | g |
| Phenylalanine, USP | 1.04 | g |
| Valine, USP | 960 | mg |
| Isoleucine, USP | 749 | mg |
| Methionine, USP | 749 | mg |
| Threonine, USP | 749 | mg |
| Tryptophan, USP | 250 | mg |
| Nonessential Amino Acids | ||
| Alanine, USP | 2.17 | g |
| Arginine, USP | 1.47 | g |
| Glycine, USP | 1.04 | g |
| Histidine, USP | 894 | mg |
| Proline, USP | 894 | mg |
| Glutamic Acid | 749 | mg |
| Serine, USP | 592 | mg |
| Aspartic Acid, USP | 434 | mg |
| Tyrosine, USP | 39 | mg |
| Sodium Metabisulfite, NF added | 30 | mg |
| Water for Injection, USP | qs | |
| Essential Amino Acids | 6.7 | g |
| Nonessential Amino Acids | 8.3 | g |
| Total Amino Acids | 15.0 | g |
| Total Nitrogen | 2.37 | g |
| Acetate* | 151 | mEq/L |
| Osmolarity (calculated) | 1383 | mOsmol/L |
| pH 5.6 (5.2–6.0) |
* Acetate from Lysine Acetate, USP and acetic acid used for pH adjustment.
The formulas for the individual amino acids are as follows:
| Essential Amino Acids | |
| Lysine Acetate | H2N(CH2)4CH(NH2)COOH•CH3COOH |
| Leucine | (CH3)2CHCH2CH(NH2)COOH |
| Phenylalanine |
 |
| Valine | (CH3)2CHCH(NH2)COOH |
| Isoleucine | CH3CH2CH(CH3)CH(NH2)COOH |
| Methionine | CH3S(CH2)2CH(NH2)COOH |
| Threonine | CH3CH(OH)CH(NH2)COOH |
| Tryptophan |
 |
| Nonessential Amino Acids | |
| Alanine | CH3CH(NH2)COOH |
| Arginine | H2NC(NH)NH(CH2)3CH(NH2)COOH |
| Glycine | H2NCH2COOH |
| Histidine |
 |
| Proline |
 |
| Glutamic Acid | HOOC(CH2)2CH(NH2)COOH |
| Serine | HOCH2CH(NH2)COOH |
| Aspartic Acid | HOOCCH2CH(NH2)COOH |
| Tyrosine |
 |
Plenamine™ 15% Amino Acids Injection provides seventeen crystalline amino acids. This completely utilizable substrate promotes protein synthesis and wound healing and reduces the rate of protein catabolism.
When enteral feeding is inadvisable, Plenamine™ 15% given by central venous infusion in combination with energy sources, vitamins, trace elements and electrolytes, will completely satisfy the requirements for weight maintenance or weight gain, depending upon the dose selected. The energy component in parenteral nutrition by central infusion may be derived solely from dextrose or may be provided by a combination of dextrose and intravenous fat emulsion. The addition of intravenous fat emulsion provides essential fatty acids and permits a dietary balance of fat and carbohydrate, at the same time offering the option of reducing the dextrose load and/or increasing the total caloric input. An adequate energy supply is essential for optimal utilization of amino acids.
Plenamine™ 15% can also be administered as part of a total parenteral nutrition program by peripheral vein when the enteral route is inadvisable and use of the central venous catheter is contraindicated.
Reduction of protein loss can be achieved by use of diluted Plenamine™ 15% in combination with dextrose or with dextrose and intravenous fat emulsion by peripheral infusion. Complete peripheral intravenous nutrition can be achieved in patients with low caloric requirements by a Plenamine™ 15% dextrose-fat regimen.
Plenamine™ 15% is indicated as an amino acid (nitrogen) source in parenteral nutrition regimens. This use is appropriate when the enteral route is inadvisable, inadequate or not possible, as when:
— Gastrointestinal absorption is impaired by obstruction, inflammatory disease or its complications, or antineoplastic therapy;
— Bowel rest is needed because of gastrointestinal surgery or its complications such as ileus, fistulae or anastomotic leaks;
— Tube feeding methods alone cannot provide adequate nutrition.
This solution should not be used in patients in hepatic coma, severe renal failure, metabolic disorders involving impaired nitrogen utilization or hypersensitivity to one or more amino acids.
Administration of amino acids solutions at excessive rates or to patients with hepatic insufficiency may result in plasma amino acid imbalances, hyperammonemia, prerenal azotemia, stupor and coma. Conservative doses of amino acids should be given to these patients, dictated by the nutritional status of the patient. Should symptoms of hyperammonemia develop, amino acid administration should be discontinued and the patient's clinical status re-evaluated.
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low.
Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
It is essential to provide adequate calories concurrently if parenterally administered amino acids are to be retained by the body and utilized for protein synthesis.
The administration of Plenamine™ 15% Amino Acids Injection as part of total parenteral nutrition (TPN) with large volumes of hyperosmotic fluids requires periodic monitoring of the patient for signs of hyperosmolarity, hyperglycemia, glycosuria and hypertriglyceridemia.
During parenteral nutrition with concentrated dextrose and amino acids solutions, essential fatty acid deficiency syndrome may develop but may not be clinically apparent. Early demonstration of this condition can only be accomplished by gas liquid chromatographic analysis of plasma lipids. The syndrome may be prevented or corrected by appropriate treatment with intravenous fat emulsions.
For complete nutritional support, TPN regimens must also include multiple vitamins and trace elements. Potentially incompatible ions such as calcium and phosphate may be added to alternate infusate bottles to avoid precipitation. Although the metabolizable acetate ion in Plenamine™ 15% diminishes the risk of acidosis, the physician must be alert to the potential appearance of this disorder.
Initiation and termination of infusions of TPN fluids must be gradual to permit adjustment of endogenous insulin release.
Undiluted Plenamine™ 15% should not be administered peripherally. When administered centrally, it should be diluted with appropriate diluents, e.g., dextrose, electrolytes and other nutrient components, to at least half strength. (See DOSAGE AND ADMINISTRATION.)
Caution against volume overload should be exercised.
Drug product contains no more than 25 mcg/L of aluminum.
Infusion of Plenamine™ 15% without concomitant infusion of an adequate number of non-protein calories may result in elevated BUN. Monitoring of BUN is required and the balance between Plenamine™ 15% and the calorie source may require adjustment. Frequent clinical evaluations and laboratory determinations are required to prevent the complications which may occur during the administration of solutions used in TPN. Laboratory tests should include blood glucose, serum electrolytes, liver and kidney function, serum osmolarity, blood ammonia, serum protein, pH, hematocrit, WBC and urinary glucose. When Plenamine™ 15% is combined with electrolytes, care should be used in administering this solution to patients with congestive heart failure, renal failure, edema, adrenal hyperactivity, acid-base imbalance and those receiving diuretics or antihypertensive therapy. Total volume infused should be closely monitored. Serum electrolytes should be monitored daily in these patients.
Studies with Plenamine™ 15% have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility.
Animal reproduction studies have not been conducted with Plenamine™ 15%. It is also not known whether Plenamine™ 15% can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Plenamine™ 15% should be given to a pregnant woman only if clearly needed.
Caution should be exercised when Plenamine™ 15% is administered to a nursing woman.
Safety and effectiveness of Plenamine™ 15% Amino Acids Injection in pediatric patients have not been established by adequate and well-controlled studies. However, the use of amino acids injections in pediatric patients as an adjunct in the offsetting of nitrogen loss or in the treatment of negative nitrogen balance is referenced in the medical literature.
TPN delivered by indwelling catheter through a central or large peripheral vein is a special technique requiring a team effort by physician, nurse and pharmacist. The responsibility for administering this therapy should be confined to those trained in the procedures and alert to signs of complications. Complications known to occur from the placement of central venous catheter are pneumothorax, hemothorax, hydrothorax, artery puncture and transection, injury to the brachial plexus, malposition of the catheter, formation of arteriovenous fistula, phlebitis, thrombosis, and air/catheter emboli. The risk of sepsis is present during intravenous therapy, especially when using central venous catheters for prolonged periods. It is imperative that the preparation of admixtures and the placement and care of the catheters be accomplished under controlled aseptic conditions.
Admixtures should be prepared under a laminar flow hood using aseptic technique.
Admixtures should be stored under refrigeration and must be administered within 24 hours after removal from refrigerator.
Filters of less than 1.2 micron pore size must not be used with admixtures containing fat emulsion.
IT IS ESSENTIAL THAT A CAREFULLY PREPARED PROTOCOL, BASED ON CURRENT MEDICAL PRACTICES, BE FOLLOWED, PREFERABLY BY AN EXPERIENCED TEAM.
In the event of overhydration or solute overload, re-evaluate the patient and institute appropriate corrective measures. (See WARNINGS and PRECAUTIONS.)
The appropriate daily dose of amino acids to be used with dextrose or with dextrose and intravenous fat emulsion will depend upon the metabolic status and clinical response of the patient as therapy proceeds. Doses which achieve nitrogen equilibrium or positive balance are the most desirable. The dosage on the first day should be approximately half the anticipated optimal dosage and should be increased gradually to minimize glycosuria; similarly, withdrawal should be accomplished gradually to avoid rebound hypoglycemia.
Fat emulsion coadministration should be considered when prolonged (more than 5 days) parenteral nutrition is required in order to prevent essential fatty acid deficiency (EFAD). Serum lipids should be monitored for evidence of EFAD in patients maintained on fat free TPN.
The amount administered is dosed on the basis of amino acids/kg of body weight/day. In general, two to three g/kg of body weight for neonates and infants with adequate calories are sufficient to satisfy protein needs and promote positive nitrogen balance. In pediatric patients, the final solution should not exceed twice normal serum osmolarity (718 mOsmol/L).
Plenamine™ 15% in a Pharmacy Bulk Package is not intended for direct infusion. The container closure may be penetrated only once using a suitable sterile transfer device or dispensing set which allows measured dispensing of the contents. The Pharmacy Bulk Package is to be used only in a suitable work area such as a laminar flow hood (or an equivalent clean air compounding area). Once the closure is penetrated, the contents should be dispensed as soon as possible; the transfer of contents must be completed within 4 hours of closure entry. The bottle may be stored at room temperature (25°C) after the closure has been entered. Date and time of container entry should be noted in the area designated on the container label.
When using Plenamine™ 15% in patients with a need for fluid volume restriction, it can be diluted as follows:
| Volume | Amount | Final Concentration | |
|---|---|---|---|
| Plenamine™ 15% | 500 mL | 75 g | 7.5% |
| Dextrose 70% | 250 mL | 175 g | 17.5% |
| Intralipid® 20% | 250 mL | 50 g | 5.0% |
This will provide 1395 kilocalories (kcal) per 1000 mL of admixture with a ratio of 118 non-protein calories per gram of nitrogen and an osmolarity of 1561 mOsmol/L.
In patients where the need for fluid restriction is not so marked, either of the following regimens may be used dependent upon the energy needs of the patient.
| Volume | Amount | Final Concentration | |
|---|---|---|---|
| Plenamine™ 15% | 500 mL | 75 g | 3.75% |
| Dextrose 50% | 1000 mL | 500 g | 25% |
| Intralipid® 20% | 500 mL | 100 g | 5% |
This will provide 1500 kcal per 1000 mL of admixture with a ratio of 228 non-protein calories per gram of nitrogen and an osmolarity of 1633 mOsmol/L.
| Volume | Amount | Final Concentration | |
|---|---|---|---|
| Plenamine™ 15% | 500 mL | 75 g | 3.75% |
| Dextrose 30% | 1000 mL | 300 g | 15% |
| Intralipid® 10% | 500 mL | 50 g | 2.5% |
This will provide 935 kcal per 1000 mL of admixture with a ratio of 158 non-protein calories per gram of nitrogen and an osmolarity of 1128.5 mOsmol/L.
In unstressed adult patients with no unusual nitrogen losses, a minimum dosage of 0.1 gram nitrogen (4.2 mL of Plenamine™ 15%) plus 4.4 grams (15 calories) of dextrose per kilogram of body weight per day are required to achieve nitrogen balance and weight stability. Intravenous fat emulsion may be used as a partial substitute for dextrose. This regimen provides a ratio of 150 non-protein calories per gram of nitrogen.
For patients stressed by surgery, trauma or sepsis, and those with unusual nitrogen losses, the dosage required for maintenance may be as high as 0.3 to 0.4 grams of nitrogen (13 to 17 mL Plenamine™ 15%) per kilogram of body weight per day, with proportionate increases in non-protein calories. Periodic assessment of nitrogen balance of the individual patient is the best indicator of proper dosage. Volume overload and glycosuria may be encountered at high dosage, and nitrogen balance may not be achieved in extremely hypermetabolic patients under these constraints. Concomitant insulin administration may be required to minimize glycosuria. Daily laboratory monitoring is essential.
Use of an infusion pump is advisable to maintain a steady infusion rate during central venous infusion.
In patients for whom central venous catheterization is not advisable, protein catabolism can be reduced by peripheral use of diluted Plenamine™ 15% plus non-protein calorie sources. Dilution of 250 mL Plenamine™ 15% in 750 mL of 10% dextrose will reduce the osmolarity to a level (724 mOsmol/L) which is more favorable to the maintenance of the integrity of the walls of the veins. Intravenous fat emulsion can be infused separately or simultaneously; if infused simultaneously the fat emulsion will provide a dilution effect upon the osmolarity while increasing the energy supply.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
To reduce the risk of bacterial contamination, all intravenous administration sets should be replaced at least every 24 hours. Usage of admixtures must be initiated within 24 hours after mixing. If storage is necessary during this 24 hour period, admixtures must be refrigerated and completely used within 24 hours of beginning administration.
Plenamine™ 15% Amino Acids Injection is supplied sterile and nonpyrogenic in glass containers, Pharmacy Bulk Packages, packaged 6 per case.
| NDC | REF | Size |
|---|---|---|
| 0264-3200-55 | S3200-SS | 1000 mL |
| 0264-3205-55 | S3205-SS | 2000 mL |
Store in the closed carton; do not expose solution to light until ready for use. Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended that the product be stored at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Brief exposure to temperatures above 25°C during transport and storage will not adversely affect the product. Solution that has been frozen must not be used.
Rx only
Revised: November 2020
Intralipid is a registered trademark of Fresenius Kabi AB.
Warning: Not for direct infusion. For preparation of admixtures for intravenous infusion.
The pharmacy bulk package is for use in a Pharmacy Admixture Service only. Use of this product is restricted to a suitable work area, such as a laminar flow hood (or an equivalent clean air compounding area).
Additives should not be made to Pharmacy Bulk Packages.
Designed for use with a vented sterile dispensing set.
The container closure may be penetrated only one time, utilizing a suitable sterile dispensing set which allows measured dispensing of the contents.
Transfer individual dose(s) to appropriate intravenous infusion solutions. Use of a syringe with needle is not recommended. Multiple entries increase the potential of the microbial and particulate contamination.
The withdrawal of container contents should be accomplished without delay using aseptic technique. Discard container no later than 4 hours after initial closure puncture.
The bottle may be stored under laminar flow hood at room temperature (25°C) after the closure has been entered. Date and time of container entry should be noted in the area designated on the container label.
B. Braun Medical Inc.
Bethlehem, PA 18018-3524 USA
1-800-227-2862
Prepared in USA.
API from Japan or USA.
LD-242-6 Y36-003-033
Plenamine™
15% Amino Acids Injection
NDC 0264-3200-55
REF S3200-SS
1000 mL
PHARMACY BULK PACKAGE - NOT FOR DIRECT INFUSION
Protect from light until use.
For Intravenous Use
Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]
Solution that has been frozen must not be used. Do not expose to light before
using. Once closure is penetrated, transfer contents promptly, total time not to
exceed 4 hours. See package insert for proper use of Pharmacy Bulk Package.
Entry Date: _______________ Time: _______________
Each 100 mL contains:
| Essential Amino Acids | |
| Lysine (from Lysine Acetate, USP) | 1.18 g |
| Leucine, USP | 1.04 g |
| Phenylalanine, USP | 1.04 g |
| Valine, USP | 960 mg |
| Isoleucine, USP | 749 mg |
| Methionine, USP | 749 mg |
| Threonine, USP | 749 mg |
| Tryptophan, USP | 250 mg |
| Nonessential Amino Acids | |
| Alanine, USP | 2.17 g |
| Arginine, USP | 1.47 g |
| Glycine, USP | 1.04 g |
| Histidine, USP | 894 mg |
| Proline, USP | 894 mg |
| Glutamic Acid | 749 mg |
| Serine, USP | 592 mg |
| Aspartic Acid, USP | 434 mg |
| Tyrosine, USP | 39 mg |
| Sodium Metabisulfite, NF added | 30 mg |
| Water for Injection USP | qs |
pH 5.6 (5.2-6.0), adjusted with acetic acid.
Acetate: 151 mEq/L, including quantity used
for pH adjustment.
Calculated Osmolarity:
1383 mOsmol/L
Contains no more than
25 mcg/L of aluminum.
Sterile, nonpyrogenic.
Single dose container.
Use only if bottle and seal
are undamaged and solution
is clear with vacuum
present.
Administer intravenously.
Rx only
B. Braun Medical Inc.
Bethlehem, PA 18018-3524 USA
1-800-227-2862
Prepared in USA.
API from Japan or USA.
LD-243-7 Y37-002-571
LIFT HERE
Lot Exp.
Plenamine™
15% Amino Acids Injection
NDC 0264-3200-55
REF S3200-SS
1000 mL
Protect from light until use.
PHARMACY BULK PACKAGE
NOT FOR DIRECT INFUSION
Each 100 mL contains:
| Essential Amino Acids | |
| Lysine (from Lysine Acetate, USP) | 1.18 g |
| Leucine, USP | 1.04 g |
| Phenylalanine, USP | 1.04 g |
| Valine, USP | 960 mg |
| Isoleucine, USP | 749 mg |
| Methionine, USP | 749 mg |
| Threonine, USP | 749 mg |
| Tryptophan, USP | 250 mg |
| Nonessential Amino Acids | |
| Alanine, USP | 2.17 g |
| Arginine, USP | 1.47 g |
| Glycine, USP | 1.04 g |
| Histidine, USP | 894 mg |
| Proline, USP | 894 mg |
| Glutamic Acid | 749 mg |
| Serine, USP | 592 mg |
| Aspartic Acid, USP | 434 mg |
| Tyrosine, USP | 39 mg |
| Sodium Metabisulfite, NF added | 30 mg |
| Water for Injection USP qs |
See adjacent panel for further product information.
This end up
For Intravenous Use
pH 5.6 (5.2-6.0), adjusted with acetic acid.
Acetate: 151 mEq/L, including quantity used
for pH adjustment.
Calculated Osmolarity: 1383 mOsmol/L
Contains no more than 25 mcg/L of aluminum.
Sterile, nonpyrogenic. Single dose container.
Use only if bottle and seal are undamaged and
solution is clear with vacuum present.
Administer intravenously.
Store at 20 to 25°C (68 to 77°F). [See USP
Controlled Room Temperature.] Solution that
has been frozen must not be used. Do not
expose to light before using. Once closure is
penetrated, transfer contents promptly, total
time not to exceed 4 hours. See package
insert for proper use of Pharmacy Bulk
Package.
Rx only
B. Braun Medical Inc.
Bethlehem, PA 18018-3524 USA
1-800-227-2862
Prepared in USA. API from Japan or USA.
LD-247-5 X12-002-499
Lot Exp.
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0264-3200-55 | ML - Milliliter | 0264-3200 | 5907ec70-5ce7-4153-831a-a3129460e6f6 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ALANINE | ACTIVE INGREDIENT | OF5P57N2ZX | 15 | |
| ARGININE | ACTIVE INGREDIENT | 94ZLA3W45F | 15 | |
| ASPARTIC ACID | ACTIVE INGREDIENT | 30KYC7MIAI | 15 | |
| GLUTAMIC ACID | ACTIVE INGREDIENT | 3KX376GY7L | 15 | |
| GLYCINE | ACTIVE INGREDIENT | TE7660XO1C | 15 | |
| HISTIDINE | ACTIVE INGREDIENT | 4QD397987E | 15 | |
| ISOLEUCINE | ACTIVE INGREDIENT | 04Y7590D77 | 15 | |
| LEUCINE | ACTIVE INGREDIENT | GMW67QNF9C | 15 | |
| LYSINE ACETATE | ACTIVE INGREDIENT | TTL6G7LIWZ | 15 | |
| METHIONINE | ACTIVE INGREDIENT | AE28F7PNPL | 15 | |
| PHENYLALANINE | ACTIVE INGREDIENT | 47E5O17Y3R | 15 | |
| PROLINE | ACTIVE INGREDIENT | 9DLQ4CIU6V | 15 | |
| SERINE | ACTIVE INGREDIENT | 452VLY9402 | 15 | |
| THREONINE | ACTIVE INGREDIENT | 2ZD004190S | 15 | |
| TRYPTOPHAN | ACTIVE INGREDIENT | 8DUH1N11BX | 15 | |
| TYROSINE | ACTIVE INGREDIENT | 42HK56048U | 15 | |
| VALINE | ACTIVE INGREDIENT | HG18B9YRS7 | 15 | |
| ALANINE | ACTIVE MOIETY | OF5P57N2ZX | 15 | |
| ARGININE | ACTIVE MOIETY | 94ZLA3W45F | 15 | |
| ASPARTIC ACID | ACTIVE MOIETY | 30KYC7MIAI | 15 | |
| GLUTAMIC ACID | ACTIVE MOIETY | 3KX376GY7L | 15 | |
| GLYCINE | ACTIVE MOIETY | TE7660XO1C | 15 | |
| HISTIDINE | ACTIVE MOIETY | 4QD397987E | 15 | |
| ISOLEUCINE | ACTIVE MOIETY | 04Y7590D77 | 15 | |
| LEUCINE | ACTIVE MOIETY | GMW67QNF9C | 15 | |
| LYSINE | ACTIVE MOIETY | K3Z4F929H6 | 15 | |
| METHIONINE | ACTIVE MOIETY | AE28F7PNPL | 15 | |
| PHENYLALANINE | ACTIVE MOIETY | 47E5O17Y3R | 15 | |
| PROLINE | ACTIVE MOIETY | 9DLQ4CIU6V | 15 | |
| SERINE | ACTIVE MOIETY | 452VLY9402 | 15 | |
| THREONINE | ACTIVE MOIETY | 2ZD004190S | 15 | |
| TRYPTOPHAN | ACTIVE MOIETY | 8DUH1N11BX | 15 | |
| TYROSINE | ACTIVE MOIETY | 42HK56048U | 15 | |
| VALINE | ACTIVE MOIETY | HG18B9YRS7 | 15 | |
| ACETIC ACID | INACTIVE INGREDIENT | Q40Q9N063P | 15 | |
| SODIUM METABISULFITE | INACTIVE INGREDIENT | 4VON5FNS3C | 15 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 15 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0264-3200 | 0264-3200-55 |
| 0264-3205 | 0264-3205-55 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION, SOLUTION / SUBCUTANEOUS | 79 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | ADJ PH | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION, EMULSION / SUBCUTANEOUS | ADJ PH | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | SOAP / TOPICAL | 0.36 %w/w | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | TABLET, CHEWABLE / ORAL | 0.2 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / INTRACARDIAC | 0.09 %w/v | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | CONCENTRATE / ORAL | 2 mg/1ml | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / PERIDURAL | NA | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | ELIXIR / ORAL | 1.07 mg/5ml | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | JELLY / VAGINAL | 1.1 %w/w | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | SOLUTION / OPHTHALMIC | 3 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | LIQUID / INTRAVENOUS | 0.2 %w/v | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | TABLET / ORAL | NA | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | SYSTEM / TOPICAL | 0.5 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION, EMULSION / INTRAMUSCULAR | ADJ PH | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION, SOLUTION / SUBCUTANEOUS | 4 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | SOLUTION / ORAL | 640 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION / INTRAVENOUS | 827 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION / INTRASYNOVIAL | ADJ PH | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | ADJ PH | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | TABLET / RECTAL | 2 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION, SOLUTION / SUBMUCOSAL | 5 %w/v | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | SOLUTION / RESPIRATORY (INHALATION) | 0.3 %w/w | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR | ADJ PH | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION / INTRALESIONAL | ADJ PH | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | SYRUP / ORAL | 10 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION, SOLUTION / INTRAVENOUS | 15 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | SUSPENSION, EXTENDED RELEASE / ORAL | 100 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | CREAM / VAGINAL | 0.35 %w/w | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / INTRABURSAL | 0.2 %w/v | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | SUSPENSION / ORAL | 12 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION, SOLUTION, CONCENTRATE / INTRAMUSCULAR | 0.15 %w/v | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / INTRA-ARTICULAR | 0.2 %w/v | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | SOLUTION / OPHTHALMIC | 0.2 %w/w | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | CAPSULE / ORAL | 0.36 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION / INTRAMUSCULAR | 22 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | SOLUTION / ORAL | 10 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS | 3 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | AEROSOL, FOAM / VAGINAL | 0.03 %w/w | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION / SOFT TISSUE | ADJ PH | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | SOLUTION / TOPICAL | ADJ PH | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | SUSPENSION/ DROPS / OPHTHALMIC | 0.1 %w/w | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION / INFILTRATION | NA | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | SOLUTION / IONTOPHORESIS | 0.05 %w/v | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | INJECTION / SUBCUTANEOUS | 22 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | TABLET / ORAL | 8 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | CAPSULE / ORAL | NA | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | SUSPENSION / TOPICAL | 0.32 %w/v | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION, SOLUTION / INTRAMUSCULAR | 96 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | LIQUID / SUBCUTANEOUS | 0.2 %w/v | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | SYSTEM / IONTOPHORESIS | 0.5 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | SPONGE / TOPICAL | ADJ PH | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION, EMULSION / INTRAVENOUS | 0.03 %w/v | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | SUSPENSION / ENDOTRACHEAL | ADJ PH | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | SOLUTION / INTRAVENOUS | 14 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / SUBMUCOSAL | 5 mg | ||
| ACETIC ACID | ACETIC ACID | Q40Q9N063P | SOLUTION/ DROPS / OPHTHALMIC | 0.09 %w/v | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | SUSPENSION / ORAL | 40 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / PERINEURAL | 0.05 %w/v | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION, SOLUTION, CONCENTRATE / SUBCUTANEOUS | 0.15 %w/v |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A091112-001 | AMINO ACIDS | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | ||
| A091112-002 | AMINO ACIDS | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 84e616aacf4f… | ||
| 2026-09-14 22:38:34 | 2026-08 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | caaa826d4ba7… | ||
| 2026-08-18 06:07:40 | 2026-07 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 011fe1cb6892… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 31067a03dcf5… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 6a471c1ec25d… | ||
| 2025-08-23 18:47 UTC | 2025-08 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | fd3edfee7708… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | b8a1b40f171c… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 03ed91905a0d… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 2680178bc6a6… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 5bbf6a4d5a75… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | d8e5a09893c0… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | d06236e962d9… | ||
| 2024-10-29 15:01 UTC | 2024-10 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 79d66fd596c7… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 301d65b070ca… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 1e350fbaab3a… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 8072bd15b7f6… | ||
| 2024-05-31 18:47 UTC | 2024-05 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 5c6f7cd8ea54… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 5d02ea3f76ae… | ||
| 2022-04-08 23:34 UTC | 2022-04 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 4b0b4de00fa7… | ||
| 2022-04-04 05:41 UTC | 2022-04 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A091112-001 | AMINO ACIDS | 15%(150GM/1000ML) | INJECTABLE / INJECTION | 2012-04-13 | 74a2ff9319b5… | ||
| 2019-12-13 00:20 UTC | 2019-12 | A091112-002 | AMINO ACIDS | 15%(300GM/2000ML) | INJECTABLE / INJECTION | 2012-04-13 | 74a2ff9319b5… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| b46b3813-86ee-4ab9-a8bd-135cb655e131 | a0aedcb7-8bf6-4e2b-a85a-dd8f1411dcfc | 2023-05-19 | Warnings, Adverse reactions | a0aedcb7-8bf6-4e2b-a85a-dd8f1411dcfc |
Adverse event summaries are temporarily unavailable. Other product information remains available.